54 completed. 54 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 54 | Completed 54 |
| Phase 2 | 2 | Completed 2 |
Follow Phosphorus Metabolism Disorders: new trials by email Literature Review of Phosphorus Metabolism Disorders trials Research Report on Phosphorus Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia AP301, Sevelamer carbonate (Renvela®), AP301 Low Dose - ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD) | Phase 3 | Completed | Alebund Pharmaceuticals | 474 | 2023-06-12 | 2025-11-17 |
| Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo - Anemia, Iron Deficiency, Hyperphosphatemia | Phase 3 | Completed | USRC Kidney Research | 289 | 2022-03-30 | 2025-08-29 |
| Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791 - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 213 | 2021-03-15 | 2023-08-02 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791, Placebo - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 169 | 2021-03-15 | 2021-10-28 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791, Placebo - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 165 | 2021-03-08 | 2021-09-08 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis KHK7791 - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 54 | 2021-03-03 | 2022-01-11 |
| Anti-FGF23 (Burosumab) in Adult Patients With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Wuerzburg University Hospital | 36 | 2021-01-07 | 2023-05-03 |
| Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients Phosphate-binder intervention, Phosphorus-restricted dietary intervention - Maintenance Hemodialysis, Hyperphosphatemia | Phase 3 | Completed | Chen Jing | 123 | 2019-11-29 | 2021-08-31 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric Citrate, Sevelamer Carbonate - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Panion & BF Biotech Inc. | 240 | 2019-06-19 | 2021-03-10 |
| Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis Ferric citrate tablet, Sevelamer carbonate tablet - Hyperphosphatemia, End Stage Renal Disease | Phase 3 | Completed | Sinomune Pharmaceutical Co., Ltd | 239 | 2019-05-24 | 2024-04-17 |
| Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH Burosumab - X-linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 35 | 2019-03-07 | 2022-05-20 |
| Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy Tenapanor, Placebo, Phosphate Binder Agents - Hyperphosphatemia | Phase 2 / Phase 3 | Completed | Ardelyx | 236 | 2019-02-28 | 2023-03-06 |
| PA21 Safety and Efficacy in Adult Chinese Subjects PA21, sevelamer carbonate - Chronic Kidney Disease Requiring Chronic Dialysis, Hyperphosphatemia | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 286 | 2018-08-31 | 2021-06-02 |
| Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets Burosumab - Hypophosphatemia, Hypophosphatemic Rickets | Phase 3 | Completed | Redwood Dermatology Sciences | 1 | 2018-01-31 | 2020-01-18 |
| A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis Tenapanor, Placebo, Sevelamer Carbonate - Hyperphosphatemia | Phase 3 | Completed | Ardelyx | 1559 | 2018-01-08 | 2023-06-29 |
| Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose - Iron Deficiency Anaemia, Iron Deficiency Anemia | Phase 3 | Completed | Pharmacosmos A/S | 122 | 2017-10-30 | 2020-02-25 |
| Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose - Iron Deficiency Anaemia, Iron Deficiency Anemia | Phase 3 | Completed | Pharmacosmos A/S | 123 | 2017-10-24 | 2020-02-25 |
| A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia KRN23 - X-linked Hypophosphatemic Rickets/Osteomalacia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 16 | 2017-07-06 | 2022-09-06 |
| Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China Placebo, Sevelamer Carbonate (GZ419831) - Hyperphosphatemia | Phase 3 | Completed | Sanofi | 202 | 2017-06-07 | 2022-03-25 |
| Efficacy and Safety of Burosumab Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With XLH burosumab, Oral Phosphate Supplement, active vitamin D - X-Linked Hypophosphatemia | Phase 3 | Completed | Kyowa Kirin, Inc. | 61 | 2016-09-08 | 2024-08-29 |
Showing 20 of 54. Sign in to see all of them.
Hyperphosphatemia (43) · Renal Insufficiency, Chronic (22) · Renal Insufficiency (11) · Kidney Failure, Chronic (10) · Familial Hypophosphatemic Rickets (7) · Hypophosphatemia (5) · Anemia, Iron-Deficiency (4) · Kidney Diseases (4) · Hyperparathyroidism (2) · Iron Deficiencies (2) · Rickets, Hypophosphatemic (2) · Bronchiolitis Obliterans Syndrome (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Chronic Pain (1)
Metabolic Diseases (54) · Nutritional and Metabolic Diseases (54) · Female Urogenital Diseases (36) · Female Urogenital Diseases and Pregnancy Complications (36) · Male Urogenital Diseases (36) · Urogenital Diseases (36) · Urologic Diseases (35) · Kidney Diseases (32) · Pathological Conditions, Signs and Symptoms (29) · Chronic Disease (28) · Disease Attributes (28) · Pathologic Processes (28) · Renal Insufficiency (17) · Calcium Metabolism Disorders (10)
Sevelamer (14) · ferric citrate (9) · burosumab (7) · cholebine (5) · lanthanum carbonate (5) · Calcium Carbonate (3) · calcium acetate (3) · tenapanor (3) · bixalomer (2) · ferric carboxymaltose (2) · ferric derisomaltose (2) · iron isomaltoside 1000 (2) · sucroferric oxyhydroxide (2) · Cinacalcet (1) · paricalcitol (1)
Astellas Pharma Inc (5) · Kyowa Kirin Co., Ltd. (5) · Tanabe Pharma Corporation (5) · Bayer (4) · Kissei Pharmaceutical Co., Ltd. (4) · Ardelyx (3) · Keryx Biopharmaceuticals (3) · Kyowa Kirin, Inc. (3) · Genzyme, a Sanofi Company (2) · Panion & BF Biotech Inc. (2) · Pharmacosmos A/S (2) · Alebund Pharmaceuticals (1) · Amgen (1) · Chen Jing (1) · Denver Nephrologists, P.C. (1)
Japan (22) · United States (20) · France (7) · Italy (7) · China (6) · Germany (6) · United Kingdom (6) · Australia (4) · Canada (4) · Poland (4) · Puerto Rico (4) · Austria (3) · Hungary (3) · South Korea (3) · Spain (3)
Julia B Lewis, MD (3) · David P Rosenbaum, PhD (2) · David P Rosenbaum, Ph.D. (1) · Geoff Block, MD (1) · Geoffrey A Block, MD (1) · Hou Fanfan, MD (1) · Jeffrey Sugarman, MD PhD (1)
PMID 40576086, PMID 38323855, PMID 39151033, PMID 42664364, PMID 32016310, PMID 36854566, PMID 37853560, PMID 21324193, PMID 23369827, PMID 23670305, PMID 24840781, PMID 25029424, PMID 25079863, PMID 26184491, PMID 26239948, PMID 26670307, PMID 29947083, PMID 31104833, PMID 31165191, PMID 32721016, PMID 33484279, PMID 33766811, PMID 34003226, PMID 34548383, PMID 35372979, PMID 35533340, PMID 35775373, PMID 35927518, PMID 36719566, PMID 37084401, PMID 37473746, PMID 37910313, PMID 37925471, PMID 42387036
2008 (1), 2014 (1), P50AR054086 (1)